SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2866)5/20/2010 1:58:31 PM
From: tuck  Read Replies (1) of 3158
 
It's been noted on IHub that HSP has extended it tender offer to June 2nd, having gotten only 78% of the shares. I've seen a couple of theories about this. One is that a large fund -- specifically Millenium, a 10% holder that filed with the SEC a couple of weeks ago that it thought the offer was too low -- was not tendering shares, thus requiring a shareholder vote. That it's a ploy by HSP to lower the price and pick up extra shares on the open market. That there really is a deal killing supply chain problem in the UK, and that Hospira wants to use this excuse to get out of the deal. I think the latter is less likely and picked up some shares this morning. My understanding is that UK rights have been outlicensed to Therabel, so that would be a pretty small issue to quibble about (hence JAV's reassurance that no such problems existed in the US, which would be something to quibble about, as Hospira is largely paying for those rights). You or anyone else have a feel?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News